Is Brilacidin safe?
Company says well tolerated; no data
CAnimal and cell studiesIn clinical trialsas of 2026-10-26
In vitro studies report low toxicity to human cells at doses that blocked virus. Human safety data from the phase 2 programmes have not been published in a journal. The company's COVID-19 topline release described side effects at similar rates in the brilacidin and placebo arms. Earlier defensin-mimetic compounds in this class raised worries about blood pressure effects and numb mouths during infusion. Public data cannot show whether brilacidin shares those effects. 123
More on Brilacidin
Citations
- Bakovic 2021, Viruses: brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture doi.org
- Hu 2022, J Med Virol: brilacidin shows broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 doi.org
- Innovation Pharmaceuticals 2021 press release: topline results from the phase 2 trial of brilacidin for COVID-19 markets.financialcontent.com
Reference information only, not medical advice. Drawn from the Brilacidin article, fact-checked against the cited sources. No dosing anywhere on this site.